Physiologically Based Pharmacokinetic Model of Plasma and Intracranial Pharmacokinetics and CDK4/6 Occupancy of Abemaciclib to Optimizing Dosing Regimen for Brain Metastatic Patients.
Ontology highlight
ABSTRACT: Objective: The study aimed to develop a physiologically based pharmacokinetic (PBPK) model to predict steady state trough concentrations (C min) and CDK4/6 occupancy in plasma and cerebrospinal fluid (CSF) for abemaciclib (ABE) and its three active metabolites. Additionally, a biomarker model was constructed to simulate changes in pRB and TOPO-IIα expression. Methods: The population PBPK and biomarker models of ABE were developed using physicochemical, pharmacokinetics (PK), CDK4/6 occupancy, biomarker, and physiological properties. These models were then validated using four clinical plasma PK studies, two CSF PK studies, and one clinically observed biomarker expression change in patients. Results: The PBPK model showed good consistency with observed
SUBMITTER: Zhang C
PROVIDER: S-EPMC11904693 | biostudies-literature | 2025 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA